Figure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors

Supplementary Fig. S2. Targeting mutant NRAS activates the STING signaling. A-B. The indicated NRAS mutant cells and wild type NRAS cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (A) and qRT-PCR analysis (n = 3 biological independent samples) (B). C-D. The indicated NRAS wild type cells A2058, A375 were transiently transfected with site-specific siRNAs targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples) (C) and western blot analysis (D). E. The schematic overview of RNA-seq in HT1080 cell lines. F-G. HT1080, ME4405, SNU719 cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (F) and qRT-PCR analysis (n = 3 biological independent samples) (G). H. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). I. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were treated with 200ng/mL poly(dA:dT) for 18h. The cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). Error bars represent mean ± SD. The p-values in B and G were determined by a two-tailed unpaired Student’s t test.The p-values in C and H-I were calculated using one-way ANOVA followed by Dunnett's multiple comparisons test, **p < 0.01. Data in A-D, F-G are representative of three independent experiments. Data in H-I are representative of two independent experiments.